Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies
- PMID: 7907208
- DOI: 10.1002/ana.410350310
Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies
Abstract
Taxol is a novel antineoplastic agent that has demonstrated impressive clinical activity in breast, ovarian, lung, and head and neck cancers. This broad antitumor activity of taxol in cisplatin-sensitive tumors suggests that the combination of taxol and cisplatin may become one of the most commonly used taxol-based chemotherapeutic regimen in the treatment of solid tumors. Both taxol and cisplatin, however, are neurotoxic. To study the neurotoxic effects of these two agents when used in combination, we prospectively evaluated neurological function at baseline, during, and following treatment, in 21 cancer patients treated with taxol (135-350 mg/m2), cisplatin (75-100 mg/m2), and granulocyte-colony stimulating factor (5 micrograms/kg). Twenty of the 21 patients (95%) developed a sensory-motor neuropathy 1 to 21 weeks after the initiation of therapy, that was progressive with each additional course of chemotherapy. The neuropathy was symmetrical, length dependent, axonal in nature by physiological studies, and more pronounced in those patients who received higher doses of taxol. The neuropathy appeared earlier and at lower taxol doses in those patients with preexisting neuropathies. We conclude that sensory-motor neuropathy is a frequent dose-dependent toxicity of combined cisplatin and taxol use. Peripheral neuropathy is likely to become the major dose-limiting toxicity of taxol-cisplatin combination chemotherapy when higher doses of these agents are administered with granulocyte-colony stimulating factor.
Similar articles
-
A phase I/II study of paclitaxel plus cisplatin as first-line therapy for head and neck cancers: preliminary results.Semin Oncol. 1995 Dec;22(6 Suppl 15):50-4. Semin Oncol. 1995. PMID: 8643971 Clinical Trial.
-
Phase I/II study of paclitaxel plus cisplatin as first-line chemotherapy for advanced non-small cell lung cancer: preliminary results.Semin Oncol. 1995 Dec;22(6 Suppl 15):29-33. Semin Oncol. 1995. PMID: 8643967 Clinical Trial.
-
A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.Semin Oncol. 1996 Oct;23(5 Suppl 11):16-22. Semin Oncol. 1996. PMID: 8893894 Clinical Trial.
-
Neurotoxicity of Taxol.J Natl Cancer Inst Monogr. 1993;(15):107-15. J Natl Cancer Inst Monogr. 1993. PMID: 7912516 Review.
-
[Paclitaxel (taxol): a review of its antitumor activity and toxicity in clinical studies].Gan To Kagaku Ryoho. 1998 Mar;25(4):605-15. Gan To Kagaku Ryoho. 1998. PMID: 9530372 Review. Japanese.
Cited by
-
Measuring vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia.Cancer Nurs. 2013 Sep-Oct;36(5):E49-60. doi: 10.1097/NCC.0b013e318299ad23. Cancer Nurs. 2013. PMID: 23842524 Free PMC article.
-
Measuring Therapy-Induced Peripheral Neuropathy: Preliminary Development and Validation of the Treatment-Induced Neuropathy Assessment Scale.J Pain. 2015 Oct;16(10):1032-43. doi: 10.1016/j.jpain.2015.07.002. Epub 2015 Jul 22. J Pain. 2015. PMID: 26210041 Free PMC article.
-
Paclitaxel Induces Upregulation of Transient Receptor Potential Vanilloid 1 Expression in the Rat Spinal Cord.Int J Mol Sci. 2020 Jun 18;21(12):4341. doi: 10.3390/ijms21124341. Int J Mol Sci. 2020. PMID: 32570786 Free PMC article.
-
Chemotherapy-induced peripheral neurotoxicity.Nat Rev Neurol. 2010 Dec;6(12):657-66. doi: 10.1038/nrneurol.2010.160. Epub 2010 Nov 9. Nat Rev Neurol. 2010. PMID: 21060341 Review.
-
Establishing a Mouse Model of a Pure Small Fiber Neuropathy with the Ultrapotent Agonist of Transient Receptor Potential Vanilloid Type 1.J Vis Exp. 2018 Feb 13;(132):56651. doi: 10.3791/56651. J Vis Exp. 2018. PMID: 29553496 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical